Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$164.99 USD

164.99
4,600,299

-2.37 (-1.42%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $164.96 -0.03 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?

Smart Beta ETF report for DGRO

Boston Scientific's (BSX) POLARx System Gets FDA Approval

Boston Scientific's (BSX) POLARx enables doctors to expand and modify the new POLARx catheter to match a patient's unique anatomy during an ablation treatment.

Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%

Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.

Sweta Killa headshot

Pharma ETFs in Focus Post Q2 Earnings

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Johnson & Johnson (JNJ) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised

Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, BAYRY Post Q2 Results, NVO's Wegovy Cuts Heart Attack Risk

Eli Lilly (LLY), Bayer (BAYRY) and Novo Nordisk (NVO) announce second-quarter results.

Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up

Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.

Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?

Smart Beta ETF report for VYM

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

Style Box ETF report for HDV

The Zacks Analyst Blog Highlights PepsiCo, Johnson & Johnson, Intuitive Surgical, Kimberly-Clark and Atmos Energy

PepsiCo, Johnson & Johnson, Intuitive Surgical, Kimberly-Clark and Atmos Energy are included in this Analyst Blog.

Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised

Halozyme (HALO) shares rise 4% in the after-market trading hours on better-than-expected second-quarter 2023 results, boosted by collaboration and royalty revenues. Management raises its 2023 guidance.

Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales

Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.

Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2

Iovance (IOVA) reports mixed second-quarter results as earnings beat estimates but sales miss the mark.

Novavax (NVAX) Q2 Earnings Beat, Stock Down 4% on '23 Sales Cut

Novavax (NVAX) reports better-than-expected Q2 earnings results, as earnings and revenues beat estimates. Shares drop due to lowered 2023 product sales guidance.

Nalak Das headshot

5 Defensive Stocks for Stable Returns Amid Recent Volatility

We have narrowed our search to five stocks from defensive sectors. These are: JNJ, PEP, ISRG, KMB, ATO.

Eli Lilly (LLY) Q2 Earnings Beat, Mounjaro Powers Sales Growth

Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its financial guidance for 2023.

Perrigo (PRGO) Beats on Q2 Earnings & Sales, Reiterates '23 View

Perrigo (PRGO) reports encouraging second-quarter 2023 results. Management reaffirms the financial guidance for 2023.

CRISPR Therapeutics (CRSP) Q2 Loss Narrower Than Expected

CRISPR Therapeutics' (CRSP) second-quarter results beat the mark for both earnings and sales.

Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q2

Karuna (KRTX) reports mixed second-quarter 2023 results. The company beats estimates for earnings but misses the mark on sales.

Bruker (BRKR) Q2 Earnings and Revenues Top, '23 Sales View Up

Bruker (BRKR) delivers better-than-expected earnings and revenues in the second quarter of 2023.